Forte Biosciences (FBRX) EBITDA (2016 - 2026)

Forte Biosciences (FBRX) has 11 years of EBITDA data on file, last reported at -$22.4 million in Q1 2026.

• On a quarterly basis, EBITDA fell 39.17% year-over-year to -$22.4 million in Q1 2026; TTM through Mar 2026 was -$77.0 million, a 71.35% decrease from a year earlier, with the FY2025 full-year figure at -$70.7 million, down 93.04% from the prior year.
• EBITDA for Q1 2026 stood at -$22.4 million, up from -$24.6 million in the prior quarter.
• Over the last five years, EBITDA for FBRX reached as high as -$2.5 million in Q1 2022 and fell as low as -$24.6 million in Q4 2025.
• Historically, EBITDA has averaged -$10.4 million across 5 years, with a median of -$8.6 million in 2024.
• Across the five-year window, EBITDA surged 55.54% in 2022 and sank 234.25% in 2025, its largest moves.
• Year by year, EBITDA stood at -$4.9 million in 2022, then fell by 29.2% to -$6.4 million in 2023, then declined by 15.2% to -$7.4 million in 2024, then sank by 234.25% to -$24.6 million in 2025, then grew by 8.68% to -$22.4 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$22.4 million in Q1 2026, -$24.6 million in Q4 2025, and -$18.4 million in Q3 2025.